Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe
Dateline City:
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Endocyte, Inc.
Language:
English
Contact:
MerckMedia:Ian McConnell, +1 908-423-3046orClaire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465orJustin Holko, +1 908-423-5088orEndocyteMedia:Martina Schwarzkopf, +1 212-845-4292orTony Russo, +1 212-845-4251orInvestors:Stephanie Ascher, +1 212-362-1200
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: ECYT Exchange: NASDAQ
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news